KASID
Search
- Page Path
- HOME > Search
Original Articles
- Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study
- Robert Gilmore, Richard Fernandes, Imogen Hartley, Arteen Arzivian, Rupert Leong, Bridgette Andrew, Abhinav Vasudevan, Tessa Greeve, Gregory Thomas Moore, Steven Kim, Daniel Lightowler, Abhey Singh, Gillian Mahy, Aditya Mithanthaya, Kannan Venugopaul, Sangwoo Han, Robert Bryant, Jack West, Jonathan Segal, Britt Christensen, Crispin Corte, Nik Ding, Yoon-Kyo An, Jakob Begun
- Received August 12, 2024 Accepted October 7, 2024 Published online December 20, 2024
- DOI: https://doi.org/10.5217/ir.2024.00127 [Epub ahead of print]
-
Abstract
PDF
PubReader
ePub - Background/Aims
Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulcerative colitis in a real-world population.
Methods
Patients that commenced upadacitinib for moderate-to-severe ulcerative colitis from September 2022 until March 2023 were identified at 13 inflammatory bowel disease centers across Australia. Clinical, biochemical, endoscopic, and intestinal ultrasound outcomes were recorded retrospectively at baseline, week 8, and week 16.
Results
One hundred and fifty-two patients (61 female [40%], median age 38 years [interquartile range, 28–50]) were included. The primary endpoint of clinical remission was met in 79% at week 8, and 84% at week 16. A total of 42 patients (28%) with prior tofacitinib exposure were included. No significant difference in clinical remission was observed by week 16 between tofacitinib experienced compared to tofacitinib naïve patients (86% vs. 84%, P= 0.67). Complete intestinal ultrasound data was available for 36 patients, showing transmural remission in 64% at week 8 and 81% at week 16, with a decrease in median bowel wall thickness of 2.3 mm and 2.4 mm, respectively.
Conclusions
Upadacitinib resulted in high rates of clinical remission at 8 and 16 weeks in this large real-world cohort of ulcerative colitis patients. Upadacitinib is effective in patients with prior tofacitinib exposure. Intestinal ultrasound shows significant rates of transmural remission at week 8, sustained through week 16. -
Citations
Citations to this article as recorded by
- Letter: Toward Intra‐Class Switching With JAK Inhibitors?
Mathieu Uzzan, David Laharie
Alimentary Pharmacology & Therapeutics.2025; 61(5): 919. CrossRef
- Letter: Toward Intra‐Class Switching With JAK Inhibitors?
- 1,641 View
- 226 Download
- 1 Web of Science
- 1 Crossref
- IBD
- Assessing quality of magnetic resonance enterography and its impact on disease assessment of ileal Crohn’s disease
- Anuj Bohra, Declan J Connoley, Danny Con, Jonathan P Segal, Olga Niewiadomski, Abhinav Vasudevan, Daniel R Van Langenberg, Numan Kutaiba
- Intest Res 2024;22(2):152-161. Published online January 5, 2024
- DOI: https://doi.org/10.5217/ir.2023.00095
-
Abstract
PDF
Supplementary MaterialPubReaderePub - Background/Aims
Assessment of quality of magnetic resonance enterography (MRE) in small bowel Crohn’s disease (CD) activity evaluation has received little attention. We assessed the impact of bowel distention and motion artifact on MRE activity indices in ileal CD.
Methods
A cohort of patients who underwent contemporaneous MRE and colonoscopy for ileal CD assessment between 2014 and 2021 at 2 centers were audited. An abdominal radiologist blinded to clinical data reviewed each MRE, graded bowel distention and motion artifact upon a pre-specified 3-point scale and calculated the original magnetic resonance index of activity (MaRIA) and simplified MaRIA (sMaRIA), London index and CD MRE index (CDMI). Ileal endoscopic activity was graded via the Simplified Endoscopy Score for CD (SES-CD). The performance of MRE indices in discriminating active disease (SES-CD ≥3) stratified by MRE quality was measured by receiver operator characteristic analyses.
Results
One hundred and thirty-seven patients had MRE and colonoscopy within a median of 16 days (range, 0–30 days) with 63 (46%) exhibiting active disease (SES-CD ≥3). Forty-four MREs (32%) were deemed low quality due to motion artifact and/or moderate to poor distention. Low-quality MREs demonstrated reduced discriminative performance between ileal SES-CD ≥3 and MRE indices (MaRIA 0.838 vs. 0.634, sMaRIA 0.834 vs. 0.527, CDMI 0.850 vs. 0.595, London 0.748 vs. 0.511, P<0.05 for all). Individually the presence of any motion artifact markedly impacted the discriminative performance (e.g., sMaRIA area under the curve 0.544 vs. 0.814, P<0.05).
Conclusions
Image quality parameters can significantly impact MRE disease activity interpretation. Quality metrics should be reported, enabling cautious interpretation in lower-quality studies. -
Citations
Citations to this article as recorded by- Magnetic resonance enterography in diagnosing and monitoring of adult-onset IgA vasculitis (Henoch-Schönlein purpura) with gastro-intestinal involvement: Report of two cases
Edoardo Conticini, Susanna Guerrini, Paolo Falsetti, Maria Antonietta Mazzei, Luca Cantarini, Bruno Frediani
The Egyptian Rheumatologist.2024; 46(2): 90. CrossRef - Advocating for Consensus: The Crucial Role of Standardised Magnetic Resonance Imaging Protocols and Image Quality Metrics in Assessment of Crohn’s Disease
Mustafa Mohamedrashed, Mayur Garg, Anuj Bohra
Journal of Crohn's and Colitis.2024; 18(9): 1524. CrossRef - Achieving high-quality magnetic resonance enterography is critical for assessing Crohn’s disease activity
Kyoung Doo Song
Intestinal Research.2024; 22(2): 117. CrossRef - Bowel preparation after mid-gut tubing enhanced the efficacy and compliance of magnetic resonance enterography in Crohn’s disease: a randomized controlled trial
Yun Wang, Min Dai, Minghui Zheng, Yan Jin, Quan Wen, Bota Cui, Zulun Zhang, Jianguo Zhu, Faming Zhang
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
- Magnetic resonance enterography in diagnosing and monitoring of adult-onset IgA vasculitis (Henoch-Schönlein purpura) with gastro-intestinal involvement: Report of two cases
- 4,093 View
- 216 Download
- 4 Web of Science
- 4 Crossref
- IBD
- Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
- Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan
- Intest Res 2022;20(1):101-113. Published online March 12, 2021
- DOI: https://doi.org/10.5217/ir.2020.00146
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
The residual risk of colectomy after infliximab salvage in steroid-refractory acute severe ulcerative colitis (ASUC) is required to inform the need for subsequent maintenance biologic therapy. The aim of this study was to determine the dynamic response of common serum biomarkers to infliximab salvage and assess their utility in predicting subsequent colectomy.
Methods
A retrospective single-center cohort study was conducted on all patients who received infliximab salvage for steroid-refractory ASUC between January 1, 2010, and July 31, 2019. Biomarkers were assessed on admission and days 1 and 3 post infliximab, and included C-reactive protein (CRP)-albumin-ratio (CAR), CRP-lymphocyte-ratio (CLR), platelet-lymphocyte-ratio (PLR) and neutrophil-lymphocyte-ratio (NLR).
Results
Of 94 patients (median age, 35 years; 67% of male), 20% required colectomy at 12 months. Biomarkers on day 3 post-infliximab best differentiated nonresponders, who had higher CRP, lower albumin and lower lymphocyte count (each P< 0.05). Day 3 predictive performance (area under the curve) for 12-month colectomy was best for CAR (0.871) and CLR (0.874), which were similar to Lindgren (0.829; P> 0.05) but superior to Mayo (0.726), partial Mayo (0.719), PLR (0.719), Ho index (0.714), NLR (0.675), Travis score (0.657) and endoscopic Mayo (0.609) (each P< 0.05). A day 3 CAR cutoff of 0.47 mg/g had 79% sensitivity, 80% specificity, 94% negative predictive value (NPV) to predict colectomy; while a day 3 CLR cutoff of 6.0 mg/109 had 84% sensitivity, 84% specificity, 96% NPV.
Conclusions
CAR and CLR measured on day 3 post infliximab salvage for steroid-refractory ASUC represent simple and routinely performed biomarkers that appear to be strong predictors of colectomy. Prospective studies are required to confirm the utility of these predictive scores. -
Citations
Citations to this article as recorded by- In Acute Severe Ulcerative Colitis Patients Who Receive Rescue Therapy, Prior Maintenance Therapy and Day 3 C-Reactive Protein After Rescue Therapy Are Associated With 12-Month Colectomy Risk
Jared A Sninsky, Ana-Maria Staicu, Edward L Barnes
Inflammatory Bowel Diseases.2024; 30(10): 1911. CrossRef - Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis
Christopher F D Li Wai Suen, Dean Seah, Matthew C Choy, Peter De Cruz
Inflammatory Bowel Diseases.2024; 30(8): 1389. CrossRef - Unresolved challenges in acute severe ulcerative colitis
Sudheer K. Vuyyuru, Vipul Jairath
Indian Journal of Gastroenterology.2024; 43(1): 9. CrossRef - Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
Seung Bum Lee, Hyun-Ki Kim, Sang Hyuk Park, Ji-Hun Lim, Sang Hyoung Park
Intestinal Research.2024; 22(1): 75. CrossRef - Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria
Makoto Naganuma, Naohiro Nakamura, Reiko Kunisaki, Katsuyoshi Matsuoka, Shojiro Yamamoto, Ami Kawamoto, Daisuke Saito, Taku Kobayashi, Kosaku Nanki, Kazuyuki Narimatsu, Hisashi Shiga, Motohiro Esaki, Shinichiro Yoshioka, Shingo Kato, Masayuki Saruta, Shin
Journal of Gastroenterology.2024; 59(4): 302. CrossRef - Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
Jihye Park
Intestinal Research.2024; 22(1): 1. CrossRef - Acute severe ulcerative colitis management: unanswered questions and latest insights
Pauline Rivière, Christopher Li Wai Suen, María Chaparro, Peter De Cruz, Antonino Spinelli, David Laharie
The Lancet Gastroenterology & Hepatology.2024; 9(3): 251. CrossRef - Predictors of adverse outcomes of steroids in patients with severe ulcerative colitis (systematic review and meta-analyses)
A. F. Mingazov, O. I. Sushkov, B. R. Kalanov, T. A. Baranova, S. I. Achkasov
Koloproktologia.2024; 23(1): 172. CrossRef - Exploring the Role of GDF-15 in Inflammatory Bowel Disease: A Case-Controlled Study Comparing Crohn’s Disease and Ulcerative Colitis with Non-Inflammatory Controls
Ondřej Kučerka, Marie Blahutová, Vít Kosek, Petra Mináriková, Jan M. Horáček, Petr Urbánek, Martin Malý
Metabolites.2024; 14(4): 185. CrossRef - Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease
Anke L Nguyen, Claudia Brick, David Liu, David J Gibson, Peter R Gibson, Miles P Sparrow
JGH Open.2024;[Epub] CrossRef - Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research
Sudheer Kumar Vuyyuru, Olga Maria Nardone, Vipul Jairath
Journal of Clinical Medicine.2024; 13(15): 4509. CrossRef - Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases
Sarah Bencardino, Ferdinando D’Amico, Alessandra Zilli, Tommaso Lorenzo Parigi, Mariangela Allocca, Gionata Fiorino, Silvio Danese, Federica Furfaro
Journal of Translational Gastroenterology.2024; 2(2): 61. CrossRef - C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis
Ryoji Koshiba, Kazuki Kakimoto, Noboru Mizuta, Keijiro Numa, Naohiko Kinoshita, Kei Nakazawa, Yuki Hirata, Takako Miyazaki, Kazuhide Higuchi, Shiro Nakamura, Hiroki Nishikawa, Senthilnathan Palaniyandi
PLOS ONE.2024; 19(8): e0305324. CrossRef - Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study
Danny Con, Peter De Cruz
Intestinal Research.2024; 22(4): 439. CrossRef - Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis
Jieqi Zheng, Zinan Fan, Chao Li, Daiyue Wang, Shenghong Zhang, Rirong Chen
BMJ Open Gastroenterology.2024; 11(1): e001587. CrossRef - Can Inflammatory Indexes Predict the Severity of Mucosal Inflammation in Ulcerative Colitis?
İrfan Küçük, Ersin Tural
Duzce Medical Journal.2024; 26(3): 191. CrossRef - Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef - Systematic review: Scores used to predict outcomes in acute severe ulcerative colitis
Maia Kayal, Hadar Meringer, Lily Martin, Jean Frederic Colombel
Alimentary Pharmacology & Therapeutics.2023; 58(10): 974. CrossRef - Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis
Xijing Huang, Ya Liu, Zhou Zhou, Yan Pan, Yinghui Zhang, Caiping Gao, Chong He
Frontiers in Medicine.2023;[Epub] CrossRef - Exploring the diagnostic and prognostic value of the C-reactive protein/lymphocyte ratio for dilated cardiomyopathy based on a real-world study
Bin Qi, Zhi-Jie Yang, Nan Huang, Wen-Bo Zheng, Chun Gui
Scientific Reports.2023;[Epub] CrossRef - Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms
Tomoyuki Hayashi, Kazuya Kitamura, Masaaki Usami, Masaki Miyazawa, Masaki Nishitani, Akihiro Dejima, Makoto Yamamoto, Shotaro Kawase, Masaya Funaki, Noriaki Orita, Hidetoshi Nakagawa, Koki Morita, Noriho Iida, Akihiro Seki, Kouki Nio, Hidenori Kido, Hideo
Inflammatory Intestinal Diseases.2023; 8(4): 133. CrossRef - Current and emerging biomarkers for ulcerative colitis
Jan K. Nowak, Rahul Kalla, Jack Satsangi
Expert Review of Molecular Diagnostics.2023; 23(12): 1107. CrossRef - Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis
Shinya Furukawa, Sen Yagi, Kana Shiraishi, Teruki Miyake, Kazuhiro Tange, Yu Hashimoto, Shogo Kitahata, Tomoe Kawamura, Tomoyuki Ninomiya, Kenichirou Mori, Seiyuu Suzuki, Naozumi Shibata, Hidehiro Murakami, Katsuhisa Ohashi, Aki Hasebe, Hideomi Tomida, Ya
BMC Gastroenterology.2022;[Epub] CrossRef - Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study
Hanyang Lin, Zhaohui Bai, Qiong Wu, Guiyang Chu, Yongguo Zhang, Xiaozhong Guo, Xingshun Qi
Frontiers in Public Health.2022;[Epub] CrossRef - Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki
Intestinal Research.2022; 20(3): 350. CrossRef - Does C-reactive protein to serum Albumin Ratio correlate with diabEtic nephropathy in patients with Type 2 dIabetes MEllitus? The CARE TIME study
Satilmis Bilgin, Ozge Kurtkulagi, Burcin Meryem Atak Tel, Tuba Taslamacioglu Duman, Gizem Kahveci, Atiqa Khalid, Gulali Aktas
Primary Care Diabetes.2021; 15(6): 1071. CrossRef - Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review
Blake O. Langley, Sara E. Guedry, Joshua Z. Goldenberg, Douglas A. Hanes, Jennifer A. Beardsley, Jennifer Joan Ryan
Journal of Clinical Medicine.2021; 10(18): 4219. CrossRef
- In Acute Severe Ulcerative Colitis Patients Who Receive Rescue Therapy, Prior Maintenance Therapy and Day 3 C-Reactive Protein After Rescue Therapy Are Associated With 12-Month Colectomy Risk
- 9,131 View
- 358 Download
- 29 Web of Science
- 27 Crossref
Review
- IBD
- The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease
- Steven Nicolaides, Abhinav Vasudevan, Tony Long, Daniel van Langenberg
- Intest Res 2021;19(2):158-170. Published online October 13, 2020
- DOI: https://doi.org/10.5217/ir.2020.00008
-
Abstract
PDFPubReaderePub
- Smoking significantly increases the risk of developing and worsens Crohn’s disease (CD), yet protects against the development and reduces the severity of ulcerative colitis. It is less clear whether smoking impacts the efficacy of therapeutics in inflammatory bowel disease (IBD). We review the literature regarding the relationship between smoking and the efficacy of medical and surgical therapy in IBD. Smoking is associated with alterations in thiopurine metabolism and may affect time to disease relapse. The outcomes of anti-tumor necrosis factor therapy in active smokers appear neutral with data lacking for newer biologics. Smoking increases the risk of postoperative recurrence in those requiring resection for CD, likely attributable to perturbations of the gut microbiota although further implications of these for disease onset/progression and treatment efficacy remain unclear. Multiple lifestyle and psychosocial confounders are likely under-recognized cofactors in the association between smoking and IBD. Despite the widely promulgated risks associated with cigarette smoking in CD, more incisive data are required to further elucidate the actual relationship between smoking and disease pathways, while accounting for the several negative cofactors prevalent in smokers which cast uncertainty on the magnitude of the direct effect of smoking on disease pathophysiology and the efficacy of therapy.
-
Citations
Citations to this article as recorded by- DAMP-ing IBD: Extinguish the Fire and Prevent Smoldering
Oliver Sandys, Pieter C. F. Stokkers, Anje A. te Velde
Digestive Diseases and Sciences.2025; 70(1): 49. CrossRef - The Effects of Combustible Cigarettes and Electronic Nicotine Delivery Systems on Immune Cell-Driven Inflammation and Mucosal Healing in Ulcerative Colitis
Nikolina Kastratovic, Vladimir Markovic, Aleksandar Arsenijevic, Ana Volarevic, Natasa Zdravkovic, Marija Zdravkovic, Marija Brankovic, Tijana Gmizic, Carl Randall Harrell, Vladimir Jakovljevic, Valentin Djonov, Vladislav Volarevic
Nicotine and Tobacco Research.2025; 27(3): 542. CrossRef - Smoking Experience before Adulthood Is Associated with an Increased Risk of Developing Ulcerative Colitis in Adult Ex-Smokers
Yu Kyung Jun, Bongseong Kim, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Kyungdo Han, Hyuk Yoon
Yonsei Medical Journal.2025; 66(1): 9. CrossRef - Recurrence rates after strictureplasty for small bowel Crohn's disease remain high in the era of biologics
A. Nasasra, T. E. M. Morrison, A. Luberto, M. Carvello, K. J. Williams, J. Davies, A. Spinelli, A. M. Mehta, J. H. Warusavitarne
Colorectal Disease.2025;[Epub] CrossRef - The Importance of Nutriepigenetics in Older Adults with Inflammatory Bowel Disease
Ana-Gabriela Prada, Costina Daniela Gîță, Sandra Monica Gîdei, Doina Istratescu, Tudor Stroie, Sorina Maria Aurelian, Gabriel Ioan Prada, Ovidiu Nicolae Penes, Anca Lucia Pop, Mihai Mircea Diculescu
Nutrients.2025; 17(4): 620. CrossRef - Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus
Shubha Bhat, Ruishen Lyu, Mitali Agarwal, Michelle Becker, Richard Bloomfeld, David H Bruining, Benjamin L Cohen, Marina Ivanov, Jonathan A Leighton, Alyssa P Stewart, Lindsay Trocke, Stacy S Tse, Ryan C Ungaro, Byron P Vaughn, Miguel Regueiro, Erick Sokn
Inflammatory Bowel Diseases.2024; 30(6): 950. CrossRef - Duration of smoking cessation in patients with inflammatory bowel disease
Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Federico Bertoletti, Antonio Giordano, Alberto López-Faba, Esther García-Planella
Gastroenterología y Hepatología.2024; 47(6): 591. CrossRef - Role of Environmental Risk Factors in the Etiology of Inflammatory Bowel Diseases: A Multicenter Study
Cemile Cansu Alperen, Barıs Soydas, Ender Serin, Mustafa Erbayrak, Nurten Akyurek Savas, Gulhan Kanat Unler, Cenk Emre Meral, Ugur Toprak, Ahmet Sedat Boyacioglu, Ulku Dagli
Digestive Diseases and Sciences.2024; 69(8): 2927. CrossRef - Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Rocío Ferreiro‐Iglesias, Sol Porto Silva, Sandra Marín, María José Casanova, Míriam Mañosa, Carlos González‐Muñoza, Ruth de Francisco, Berta Caballol, Lara Arias, Marta Piqueras, Yamile Zabana, Montserrat Rivero, Xavier Calvet, Francisco Mesonero, Pilar V
Alimentary Pharmacology & Therapeutics.2024; 60(5): 604. CrossRef - Akkermansia muciniphila and Parabacteroides distasonis as prognostic markers for relapse in ulcerative colitis patients
Ana Mendes-Frias, Marta Moreira, Maria C. Vieira, Joana Gaifem, Patrício Costa, Luís Lopes, Ricardo Silvestre
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef - Duration of smoking cessation in patients with inflammatory bowel disease
Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Federico Bertoletti, Antonio Giordano, Alberto López-Faba, Esther García-Planella
Gastroenterología y Hepatología (English Edition).2024; 47(6): 591. CrossRef - Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease—A Prospective Multicenter Cohort Study
Mirabella Zhao, Lone Larsen, Anders Dige, Anja Poulsen, Bobby Lo, Mohamed Attauabi, Pernille Dige Ovesen, Mads Damsgaard Wewer, Dagmar Christiansen, Christian Lodberg Hvas, Andreas Munk Petersen, Flemming Bendtsen, Jakob Seidelin, Johan Burisch
Journal of Crohn's and Colitis.2024;[Epub] CrossRef - Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010–2019
Ryan A. Jasper, Po‐Hung Chen, Reeha Patel, Shelly Joseph, Steven D. Miller, Susan Hutfless
JGH Open.2023; 7(4): 291. CrossRef - Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
Jiryeon Jang, Sehoon Jeong
BioChip Journal.2023; 17(4): 403. CrossRef - High-Dimensional DNA Methylation Mediates the Effect of Smoking on Crohn’s Disease
Tingting Wang, Pingtian Xia, Ping Su
Frontiers in Genetics.2022;[Epub] CrossRef - Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef - Clinical profile, course and outcomes of adults with inflammatory bowel disease over a decade: a single center experience
Reham Saleh Aljohani, Ali Alaklabi, Yumna Mohammed Alsitary, Majd Abdulrahman bin Khunayn, Shahd Omar Hijazi, Rema Ibraheem Alshagary, Rajkumar Rajendram
Annals of Saudi Medicine.2022; 42(6): 397. CrossRef
- DAMP-ing IBD: Extinguish the Fire and Prevent Smoldering
- 9,315 View
- 202 Download
- 18 Web of Science
- 17 Crossref
Case Report
- Inflammatory bowel diseases
- Inflammatory bowel disease and superior mesenteric artery thromboembolism
- Steven Nicolaides, Abhinav Vasudevan, Daniel Van Langenberg
- Intest Res 2020;18(1):130-133. Published online September 3, 2019
- DOI: https://doi.org/10.5217/ir.2019.00068
-
Abstract
PDFPubReaderePub
- While patients with inflammatory bowel disease are known to be at increased risk of venous thromboembolism, the risk of arterial thrombosis is less well recognized. Here, we describe the case of a middle-aged female with a recent diagnosis of Crohn’s disease who presented to her local emergency department with acute abdominal pain. Subsequent investigations revealed a thrombus in the superior mesenteric artery resulting in multi-organ infarction requiring major intra-abdominal surgery and extensive resection of segments of small and large bowel.
-
Citations
Citations to this article as recorded by- Navigating the Gut-Cardiac Axis: Understanding Cardiovascular Complications in Inflammatory Bowel Disease
Tanya Sinha, Zukhruf Zain, Syed Faqeer Hussain Bokhari, Sarosh Waheed, Taufiqa Reza, Anthony Eze-Odurukwe, Mitwa Patel, Mohammed Khaleel I KH Almadhoun , Azlaan Hussain, Ibrahim Reyaz
Cureus.2024;[Epub] CrossRef - Microscopic Colitis: An Underestimated Disease of Growing Importance
Kamil Rutkowski, Karina Udrycka, Barbara Włodarczyk, Ewa Małecka-Wojciesko
Journal of Clinical Medicine.2024; 13(19): 5683. CrossRef - Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
Gut and Liver.2022; 16(4): 555. CrossRef - Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview
Dhir Gala, Taylor Newsome, Nicole Roberson, Soo Min Lee, Marvel Thekkanal, Mili Shah, Vikash Kumar, Praneeth Bandaru, Vijay Gayam
Diseases.2022; 10(4): 73. CrossRef
- Navigating the Gut-Cardiac Axis: Understanding Cardiovascular Complications in Inflammatory Bowel Disease
- 7,260 View
- 208 Download
- 4 Web of Science
- 4 Crossref
First
Prev
